About
Eloxx Pharmaceuticals focuses on the discovery, development, and commercialization of compounds for the treatment of rare genetic diseases including cystic fibrosis, Duchenne muscular dystrophy, Usher syndrome, ataxia-telangiectasia, beta thalassemia, and Tay-Sachs Hurler syndrome. Its platform technologies are uniquely positioned to transform genetic diseases by correcting two defects, nonsense mutations implicated in many rare diseases and ribosomal mutations driving cancer.
The companys approach allows it to move rapidly from a target drug-discovery program to clinical drug candidates. Eloxx Pharmaceuticals is building a pipeline of molecules designed for an array of genetic diseases caused by nonsense mutations.
In June 2017, Eloxx Pharmaceuticals reverse-merged with Sevion Therapeutics Inc. This acquisition transitioned Eloxx from a private to a publicly traded company.
Funding history · 2 rounds · $98.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- When did Eloxx Pharmaceuticals become a publicly traded company?
- Eloxx Pharmaceuticals transitioned to a publicly traded company in June 2017 through a reverse-merger with Sevion Therapeutics Inc.
- What was the total amount raised by Eloxx Pharmaceuticals in its Series C funding round?
- In August 2017, Eloxx Pharmaceuticals secured a total of $38,000,000 in its Series C funding round, with investors including Korea Investment Partners and Phil Frost. For a full financing history, please refer to startupim.
- When did Eloxx Pharmaceuticals acquire Zikani Therapeutics?
- Eloxx Pharmaceuticals acquired Zikani Therapeutics in April 2021 for $7,600,000.
- What significant regulatory designation did Eloxx Pharmaceuticals receive for ELX-02 in August 2020?
- In August 2020, Eloxx Pharmaceuticals received U.S. Orphan Drug Designation for ELX-02 for the treatment of Cystic Fibrosis.
- What was the outcome of the Phase 2 combination clinical trial of ELX-02 for Class 1 Cystic Fibrosis patients, as reported in September 2022?
- In September 2022, Eloxx Pharmaceuticals reported that the Phase 2 combination clinical trial of ELX-02 in Class 1 Cystic Fibrosis (CF) patients failed to meet its primary goal.
- What new development program did Eloxx Pharmaceuticals announce for ELX-02 in March 2022?
- In March 2022, Eloxx Pharmaceuticals announced a new development program for ELX-02 for the treatment of Alport Syndrome.
- What was the purpose of the exclusive agreement between Almirall and Eloxx Pharmaceuticals in March 2024?
- In March 2024, Almirall and Eloxx Pharmaceuticals entered into an exclusive agreement to license ZKN-013 for rare dermatological diseases.
- What was the key finding from the Phase 2 study of ELX-02 for Alport Syndrome patients, as reported in September 2023?
- In September 2023, Eloxx Pharmaceuticals reported independent confirmation of positive biopsy results in all Alport Syndrome patients treated with ELX-02 in the Phase 2 clinical study.
- When did Eloxx Pharmaceuticals announce the FDA clearance to begin a Single Ascending Dose Study of ZKN-013?
- Eloxx Pharmaceuticals announced FDA clearance to begin a Single Ascending Dose Study of ZKN-013 in May 2023.